BridgeBio Pharma, Inc. BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

BBIO

Rangering i aksjer #1617
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Aksjekurs
$67.98
Markedsverdi
$13.29B
Endring (1 dag)
0.06%
Endring (1 år)
20.83%
Land
US
Handel BridgeBio Pharma, Inc. (BBIO)

Kategori

Healthcare
Antall utestående aksjer for BridgeBio Pharma, Inc. (BBIO)
Antall utestående aksjer per June 2026: 195.79M
Ifølge BridgeBio Pharma, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 195.79M. Ved slutten av December 2023 hadde selskapet 162.79M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for BridgeBio Pharma, Inc. (BBIO) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 195.79M 5.22%
2024 186.08M 14.30%
2023 162.79M 10.39%
2022 147.47M 2.16%
2021 144.36M 22.34%
2020 118.00M 12.27%
2019 105.10M 13.83%
2018 92.33M 0.00%
2017 92.33M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 29.68%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 102.26%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 144.61%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -68.24%
NL